2016
Mortality According to CD4 Count at Start of Combination Antiretroviral Therapy Among HIV-infected Patients Followed for up to 15 Years After Start of Treatment: Collaborative Cohort Study
May MT, Vehreschild JJ, Trickey A, Obel N, Reiss P, Bonnet F, Mary-Krause M, Samji H, Cavassini M, Gill MJ, Shepherd LC, Crane HM, Monforte A, Burkholder GA, Johnson MM, Sobrino-Vegas P, Domingo P, Zangerle R, Justice AC, Sterling TR, Miró JM, Sterne JAC, Collaboration F, Boulle A, Stephan C, Miro J, Cavassini M, Chêne G, Costagliola D, Dabis F, Monforte A, del Amo J, Van Sighem A, Fätkenheuer G, Gill J, Guest J, Haerry D, Hogg R, Justice A, Shepherd L, Obel N, Crane H, Smith C, Reiss P, Saag M, Sterling T, Teira R, Williams M, Zangerle R, Sterne J, May M, Ingle S, Trickey A. Mortality According to CD4 Count at Start of Combination Antiretroviral Therapy Among HIV-infected Patients Followed for up to 15 Years After Start of Treatment: Collaborative Cohort Study. Clinical Infectious Diseases 2016, 62: 1571-1577. PMID: 27025828, PMCID: PMC4885653, DOI: 10.1093/cid/ciw183.Peer-Reviewed Original ResearchConceptsStart of ARTMortality rate ratiosCombination antiretroviral therapyAntiretroviral therapyMortality of patientsCD4 countMortality rateLow baseline CD4 countYears of ARTBaseline CD4 countHigher baseline CD4Collaborative Cohort StudyStart of treatmentNorth American cohortStrong inverse associationLong-term survivalShort-term survivalBaseline CD4CD4 groupCohort studyInverse associationPatientsAmerican cohortYears durationMortality
2003
Long-Term HIV/AIDS Survival Estimation in the Highly Active Antiretroviral Therapy Era
King JT, Justice AC, Roberts MS, Chang CC, Fusco JS. Long-Term HIV/AIDS Survival Estimation in the Highly Active Antiretroviral Therapy Era. Medical Decision Making 2003, 23: 9-20. PMID: 12583451, DOI: 10.1177/0272989x02239652.Peer-Reviewed Original ResearchConceptsCells/mm3Long-term survivalCD4 cell countAge-associated mortalityTreatment failureHIV/AIDSUS life tablesCell countActive antiretroviral therapy (HAART) eraBaseline CD4 cell countHIV/AIDS patientsLong-term survival dataShort-term survival dataAntiretroviral therapy eraPre-HAART cohortTreatment mortality rateActive antiretroviral therapyTreatment failure rateRisk of mortalitySurvival dataShort-term survivalHAART failureTherapy eraAntiretroviral therapyObservational cohort
1998
ENZYME-LINKED IMMUNOSORBENT ASSAY SPOT DETECTION OF INTERFERON-γ AND INTERLEUKIN 5-PRODUCING CELLS AS AS PREDICTIVE MARKER FOR RENAL ALLOGRAFT FAILURE1
Tary-Lehmann M, Hricik DE, Justice AC, Potter NS, Heeger PS. ENZYME-LINKED IMMUNOSORBENT ASSAY SPOT DETECTION OF INTERFERON-γ AND INTERLEUKIN 5-PRODUCING CELLS AS AS PREDICTIVE MARKER FOR RENAL ALLOGRAFT FAILURE1. Transplantation 1998, 66: 219-224. PMID: 9701268, DOI: 10.1097/00007890-199807270-00014.Peer-Reviewed Original ResearchConceptsIL-5 ratiosGraft dysfunctionPeripheral blood lymphocytesAllograft failureIFN-gammaTransplant recipientsHigh riskIsolated peripheral blood lymphocytesEnzyme-linked immunosorbent spotAcute allograft dysfunctionAcute graft dysfunctionAllograft rejection episodesChronic graft dysfunctionFuture graft lossImproved renal functionRenal allograft recipientsRenal transplant recipientsAcute renal failureProlong graft survivalUseful prognostic markerShort-term survivalAllograft dysfunctionAllograft recipientsGraft functionGraft loss